Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13594762 | 0.86 | LMNA (0.50) | LMNAHSP90AA1HSP90AB1 | |
| SCHEMBL2031057 | 0.82 | ALDH1A1 (0.49) | ALDH1A1SMYD3HPGDSNPY5REPHX2 | |
| SCHEMBL4281475 | 0.81 | HPGD (0.53) | ALDH1A1LMNAMAPTSMN1; SMN2KMT2A | |
| SCHEMBL28760211 | 0.80 | POLB (0.38) | ALDH1A1LMNAMAPTSMN1; SMN2KMT2A | |
| SCHEMBL958059 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMYD3EPHX2LMNAMAPT | |
| SCHEMBL12000435 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMYD3EPHX2LMNAMAPT | |
| SCHEMBL2035287 | 0.79 | HPGD (0.42) | ALDH1A1SMYD3SMN1; SMN2 | |
| SCHEMBL953721 | 0.79 | L3MBTL1 (0.53) | ALDH1A1MAPTKMT2A | |
| SCHEMBL13993601 | 0.74 | CD38 (0.45) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8262590 | 0.74 | MEN1 (0.45) | ALDH1A1SMYD3HPGDSNPY5REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20100021420-A1 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090318430-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318430-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090142337-A1 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment | ASTEX THERAPEUTICS LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-20090142337-A1 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment | ASTEX THERAPEUTICS LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| WO-2008009954-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008007122-A2 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008001101-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007129066-A1 | 4- (2,6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-3-CARBOXYLIC ACID (1-METHANESULPHONYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129062-A1 | PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318430-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | CDK1, CCNO, CDK14 | ALDH1A1 3995/4885SMYD3 2358/4885HPGDS 475/4885 |
| US-20100021420-A1 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | CDK9, CDK1, CDK19 | ALDH1A1 3152/4885SMYD3 1372/4885HPGDS 2530/4885 |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA5A, PDK4 | ALDH1A1 95/4885SMYD3 2179/4885HPGDS 2111/4885 |
| US-20090142337-A1 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment | CDK1, CDK4, CDK3 | ALDH1A1 2379/4885SMYD3 2126/4885HPGDS 3504/4885 |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | SLC10A1, CYP11B2, SDHB | ALDH1A1 495/4885SMYD3 4636/4885HPGDS 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.